

Survey National Healthcare Long Term Care Facility Component—Annual Facility Survey

Page 1 of 6

Instructions for this form can be accessed: https://www.cdc.c	gov/nhsn/forms/instr/57.137-toi-annual-facility-survey.pdf		
*Required for saving	Tracking #:		
Facility ID:	*Survey Year:		
*National Provider ID:	State Provider #:		
Facility Characteristics			
*Ownership (check one):			
☐ For profit ☐ Not for profit, including churc	h \square Government (not VA) \square Veterans Affairs		
*Certification (check one):			
☐ Dual Medicare/Medicaid ☐ Medicare only	\square Medicaid only \square State only		
*Affiliation (check one):	☐ Independent, continuing care retirement community		
\square Multi-facility organization (chain) \square Hospital system	m, attached		
In the previous calendar year: *Average daily census:			
	age length of stay for short-stay residents:age length of stay for long-stay residents:		
*Total number of new admissions:			
*Number of Beds: *Number of Pediatric Be *Indicate which of the following primary service types are pro the number of residents receiving those services (list only or resident census on day of survey completion):	ovided by your facility. On the day of this survey, indicate		
Primary Service Type	Service provided? Number of residents		
a. Long-term general nursing:			
b. Long-term dementia:			
c. Skilled nursing/Short-term (subacute) rehabilitation:			
d. Long-term psychiatric (non-dementia):			
e. Ventilator:			
f. Bariatric:			
g. Hospice/Palliative:			
h. Other:			
Assurance of Confidentiality: The voluntarily provided information obtained in this suncollected with a guarantee that it will be held in strict confidence, will be used only for tonsent of the individual, or the institution in accordance with Sections 304, 306 and 3 Public reporting burden of this collection of information is estimated to average 135 mi existing data sources, gathering and maintaining the data needed, and completing and and a person is not required to respond to a collection of information unless it displays estimate or any other aspect of this collection of information, including suggestions for 74, Atlanta, GA 30333, ATTN: PRA (0920-0666).	the purposes stated, and will not otherwise be disclosed or released without the 08(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). Inutes per response, including the time for reviewing instructions, searching direviewing the collection of information. An agency may not conduct or sponsor, a currently valid OMB control number. Send comments regarding this burden		
CDC 57.137 (Front) Rev 13.0 Release- January 2025	Continued >>		



N-SN National Parker 2 C

Facility Microbiology Laboratory Practices			
*1. Does your facility have its own laboratory that performs mic	robiology/antimicrobial susceptibility testing?		
☐ Yes ☐ No			
If No, where is your facility's antimicrobial susceptibility t	esting performed? (check one)		
\square Affiliated medical center, within same heal	th system \square Medical center, contracted locally		
☐ Commercial referral laboratory			
*2. Indicate whether your facility screens new admissions for a (MDROs): (check all that apply)	ny of the following multidrug-resistant organisms		
\square We do not screen new admissions for MDROs			
☐ Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) If checked, indicate the specimen types sent for scr	eening: (check all that apply)		
\square Nasal swabs \square Wound swabs	☐ Sputum ☐ Other skin site		
☐ Vancomycin-resistant <i>Enterococcus</i> (VRE)			
If checked, indicate the specimen types sent for scr	eening: (check all that apply)		
\square Rectal swabs \square Wound swabs	☐ Urine		
 Multidrug-resistant gram-negative rods (includes cark resistant Acinetobacter, etc.) If checked, indicate the specimen types sent for scr 			
\square Rectal swabs \square Wound swabs	☐ Sputum ☐ Urine		
☐ Candida Auris (C.Auris) If checked, indicate the specimen types sent for scr	eening: (check all that apply)		
☐ Skin (axilla/groin)	Nares		
*3. What is the primary testing method for <i>C. difficile</i> used mos where your facility's testing is performed? (check one)	t often by your facility's laboratory or the outside laboratory		
\square Enzyme immunoassay (EIA) for toxin	☐ GDH plus NAAT (2-step algorithm)		
☐ Cell cytotoxicity neutralization assay	☐ GDH plus EIA for toxin, followed by NAAT for discrepant results		
☐ Nucleic acid amplification test (NAAT) (e.g., PCR, LAMP)	☐ Culture (<i>C. difficile</i> culture followed by detection of toxins)		
\square NAAT plus EIA, if NAAT positive (2-step algorithm)	☐ Other (specify):		
☐ Glutamate dehydrogenase (GDH) antigen plus EIA for toxin (2-step algorithm)			
("Other" should not be used to name specific laboratories, reference laboratories, or the brand names of <i>C. difficile</i> tests; most methods can be categorized accurately by selecting from the options provided. Please ask your laboratory, refer to the Tables of Instructions for this form, or conduct a search for further guidance on selecting the correct option to report.)			
*4. Does your laboratory provide a report summarizing the percent of antibiotic resistance seen in common organisms identified in cultures sent from your facility (often called an antibiogram)?			
☐ Yes ☐ No			
If Yes, how often is this summary report or antibiogram pr	ovided to your facility? (check one)		
\Box Once a year \Box Every 2 years	☐ Other (specify):		
	Continued >>		



National Pedite 2

Infectio	on Prevention and Control Practices	
	ddition to the Infection Preventionist (IP) role, how many other roles is the IP responsible for? Select all that apply: Director of Nursing	
	Assisted Director of Nursing	
	Floor Nurse (clinical)	
	Administrator	
	Other	
	t formal training has your Infection Preventionist received? Select all that apply: None	
	Infection Prevention Training Course through CDC	
	Infection Prevention Training Course through State Health Department	
	Other	
*7. Wha	t certification has your infection preventionist obtained? Select all that apply:	
	None	
	Certification in Infection Control (CIC)	
	Long-Term Care Certification in Infection Prevention (LTC-CIP)	
	Other	
*8. How many times in the past year have you had to find a new employee to take over the Infection Preventionist (IP) role? In other words, how many times has this position "turned over"? (check one)		
	Did not turn over the IP role in the past year	
	Once	
	Twice	
	Three	
	Four or more	
*9. Total facility:	I infection preventionist hours per week dedicated to infection prevention and control activity in	
	otal hours per week performing surveillance: otal hours per week for infection prevention and control activities other than surveillance:	
	t a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with SA? (check one)	
	Yes, all infected and colonized residents with MRSA	





NATIONAL HEALTHCARE SAFETY NETWORK

Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device) No
*11. Is it a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with VRE? (check one)
\square Yes, all infected and colonized residents with VRE
 ☐ Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device) ☐ No
*12. Is it a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with CRE? (check one)
\square Yes, all infected and colonized residents with CRE
☐ Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device)
□ No
*13. Is it a policy in your facility that use of gowns/gloves are required for care of residents infected or colonized with ESBL-producing or extended spectrum cephalosporin resistant Enterobacteriaceae? (check one)
\square Yes, all infected and colonized residents with ESBL
 ☐ Yes, only those with certain characteristics that make them high-risk for transmission (e.g., wounds, , presence of an indwelling device) ☐ No
*14. When a resident colonized or infected with an MDRO is transferred to another facility, does your facility communicate the resident's MDRO status to the receiving facility at the time of transfer?
Continued >>





National Beathcaren

Infection Prevention and Control Practices (continued)			
*15. Among residents with an MDRO admitted to your facility from other healthcare facilities, what percentage of the time does your facility receive information from the transferring facility about the resident's MDRO status?			
Antibiotic Stewardship Practices			
*16. Are there one or more individuals responsible for the impact antimicrobials at your facility?	t of activities to improve use of $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \$	es 🗆 No	
If Yes, what is the position of the individual(s)? (select all that apply)			
\square Medical director \square Director of Nursing	☐ Infection Preventionist		
\square Consultant Pharmacist \square Other (please speci	fy):		
*17. Does your facility have a policy that requires prescribers to antimicrobials in the medical record or during order entry?	document an indication for all	es 🗆 No	
If Yes, has adherence to the policy to document an indic	ation been monitored?	es 🗆 No	
*18. Does your facility provide treatment recommendations for common infections based on national guidelines to assist with antimicrobial decision making?		es 🗆 No	
If Yes, has adherence to facility-specific treatment recor	mmendations been monitored? \(\subseteq \cdot \)	es 🗌 No	
*19. Is there a formal procedure for performing a follow-up asses antimicrobial start to determine whether the antimicrobial is (e.g. antibiotic time out)?		es 🗆 No	
*20. Is there a formal procedure for reviewing courses of antimicrobial therapy and communicating with prescribers on antimicrobial selection, dosing, or duration of therapy (i.e., audit and feedback) at your facility?		es 🗆 No	
*21 Doos your facility have a system for tracking antimicrobial u	Soci		
*21. Does your facility have a system for tracking antimicrobial use? If yes, what is the source of the antimicrobial use report provided?		es 🗆 No	
\square Pharmacy services \square E	Electronic Health Records		
\square Manual reporting (i.e., facility infection control log) \square (Other (please specify):		
*22. Has your facility provided education to clinicians and other f antimicrobial use in the past 12 months?	acility staff on improving	es 🗆 No	
*23. Does your facility have a written statement of support from improve antimicrobial use?	Y (
		Continued >>	





rage 5 01 0				
Antibiotic Stewardship Practices (continued)				
*24. Are antimicrobial use and resistance data reviewed by leadership in quality assurance/performance improvement committee meetings?			☐ Yes ☐ No	
*25. Does your facility have access to individual(s) with antimicrobial stewardship expertise (e.g., consultant pharmacist trained in antimicrobial stewardship, stewardship team at referral hospital, external infectious disease/stewardship consultant)?				
Electronic Health Record Uti	lization			
*26. Indicate whether any of th	e following are available in a	n <u>electronic health record</u> (che	ck all that apply):	
☐ Microbiology lab cul susceptibility results		\square Medication orders		
\square Medication administ	tration record	\square Resident vital signs		
\square Resident admission	notes	\square Resident progress notes		
\square Resident transfer or	discharge notes	\square None of the above		
Facility Water Management a	and Monitoring Program			
27. Have you ever conducted a facility risk assessment to identify where <i>Legionella</i> and other opportunistic waterborne pathogens (e.g. <i>Pseudomonas, Acinetobacter, Burkholderia, Stenotrophomonas,</i> nontuberculous mycobacteria, and fungi) could grow and spread in the facility water system (e.g., piping infrastructure)? If Yes, when was the most recent assessment conducted? (Check one)				
$\square \le 1$ year ago		\square >1 and \le 3 years ago		
\square > 3 years ago				
28. Does your facility have a water management program to prevent the growth and transmission of <i>Legionella</i> and other opportunistic waterborne pathogens? If Yes, who is represented on the team? (Check all that apply)				
☐ Facility Administrator	☐ Nursing Leadership (e.g., DON or ADON)	☐ Consultant	☐ Facilities Manager/ Engineer	
\square Maintenance Staff	☐ Infection Preventionist	☐ Risk/Quality Management Staff	☐ Medical Director	
\square Equipment/ Chemical	□ Otl	her (specify):		
29. Do you regularly monitor the following parameters in your building's water system? (Check all that apply) Disinfectant (such as residual chlorine)				



N-SN National Healtinage 6 of 6

Network					
TVC TWO TK	Temperature	☐ Yes	□ No		
	If Yes, do you have a plan for corrective temperatures are not within acceptable I your water management program?		nined by	☐ Yes	□ No
	Heterotrophic plate counts	☐ Yes	□ No		
	If Yes, do you have a plan for corrective heterotrophic plate counts are not within determined by your water management	acceptable lim	nits as	☐ Yes	□ No
	Specific tests for Legionella	☐ Yes	□ No		
	If Yes, do you have a plan for corrective tests for <i>Legionella</i> are not within accept by your water management program?			☐ Yes	□ No